{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:11:43Z","timestamp":1782951103196,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1038\/sj.bjc.6604371","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T13:51:40Z","timestamp":1211982700000},"page":"1774-1780","source":"Crossref","is-referenced-by-count":38,"title":["A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers"],"prefix":"10.1038","volume":"98","author":[{"name":"on behalf of the Scottish Gynaecological Cancer Trials Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P A","family":"Vasey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Guastalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E P","family":"Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Carty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,27]]},"reference":[{"issue":"Suppl 7","key":"BF6604371_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0093-7754(03)70010-4","volume":"30","author":"CL Arteaga","year":"2003","unstructured":"Arteaga CL (2003) Targeting HER1\/EGFR: a molecular approach to cancer therapy. Semin Oncol 30 (Suppl 7): 3\u20137","journal-title":"Semin Oncol"},{"key":"BF6604371_CR2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"du Bois A, L\u00fcck H-J, Meier W, Adams H-P, M\u00f6bus V, Costa S, Bauknecht T, Richter B, Warm M, Schr\u00f6der W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Instit 95: 1320\u20131330","journal-title":"J Natl Cancer Instit"},{"issue":"Suppl 8","key":"BF6604371_CR3","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","volume":"16","author":"A du Bois","year":"2005","unstructured":"du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey PA, Vergote I, Verheijen R, Wagner U, Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC\/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 16 (Suppl 8): viii7\u2013viii12","journal-title":"Ann Oncol"},{"key":"BF6604371_CR4","first-page":"21a","volume":"21","author":"B Forouzesh","year":"2002","unstructured":"Forouzesh B, Hidalgo M, Takimoto C, de Bono JS, Forero L, Muralidhar Beeram, Malik S, Patnaik A, Rizzo J, Hammond LA, Schwartz G, Goetz A, Mays T, Kiene A, Norris J, Tolcher A, Rowinsky EK, Nadler P, Wood D, Zitelli A (2002) Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc Am Soc Clin Oncol 21: 21a (abstract 81)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Part I","key":"BF6604371_CR5","first-page":"627s","volume":"23","author":"U Gatzemeier","year":"2005","unstructured":"Gatzemeier U, Heller A, Foernzler D, Moecks J, Ward C, de Rosa F, Sauter G, Brennescheidt U (2005) Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +\/\u2212 erlotinib (TALENT). J Clin Oncol 23 (Part I): 627s (abstract 7028)","journal-title":"J Clin Oncol"},{"key":"BF6604371_CR6","first-page":"617","volume":"23","author":"U Gatzemeier","year":"2004","unstructured":"Gatzemeier U, Pluzanska A, Szxzesna A, Kaukel E, Roubec J, Brennscheidt U, De Rosa F, Mueller B, von Pawel J (2004) Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 23: 617 (abstract 7010)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6604371_CR7","unstructured":"Globocan (2002) www-dep.iarc.fr accessed 16 May 2006"},{"key":"BF6604371_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1525-1438.2005.00137.x","volume":"15","author":"AN Gordon","year":"2005","unstructured":"Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E (2005) Efficacy and safety of erlotinib HCL, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15: 785\u2013792","journal-title":"Int J Gynecol Cancer"},{"key":"BF6604371_CR9","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","volume":"23","author":"RS Herbst","year":"2005","unstructured":"Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892\u20135899","journal-title":"J Clin Oncol"},{"key":"BF6604371_CR10","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","volume":"19","author":"M Hidalgo","year":"2001","unstructured":"Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267\u20133279","journal-title":"J Clin Oncol"},{"key":"BF6604371_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/01.cad.0000127664.66472.60","volume":"15","author":"B Higgins","year":"2004","unstructured":"Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G (2004) Antitumor activity of erlotinib (OSI-774, Tarceva\u2122) alone or in combination in human non-small-cell lung cancer tumor xenograft models. Anticancer Drugs 15: 503\u2013512","journal-title":"Anticancer Drugs"},{"issue":"16 Part 2","key":"BF6604371_CR12","first-page":"6095s","volume":"9","author":"R Jones","year":"2003","unstructured":"Jones R, Hanauske A, Diaz-Rubio E, Cassidy J, Bolling C, sastre J, Rakhit A, Fettner S, Brennscheidt U, Feyereislova A (2003) Final evaluation of Tarceva\u2122 (Erlotinib) in combination with FOLFOX4 in patients with solid tumors. Clin Cancer Res 9 (16 Part 2): 6095s (abstract A108)","journal-title":"Clin Cancer Res"},{"key":"BF6604371_CR13","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/S0959-8049(97)00363-8","volume":"33","author":"SB Kaye","year":"1997","unstructured":"Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J (1997) Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer \u2013 an updated overview. Eur J Cancer 33: 2167\u20132170","journal-title":"Eur J Cancer"},{"key":"BF6604371_CR14","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/0959-8049(92)90538-D","volume":"28A","author":"M Kohler","year":"1992","unstructured":"Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner E (1992) Epidermal growth factor receptor and transforming growth factor alpha expression in human ovarian carcinomas. Eur J Cancer 28A: 1432\u20131437","journal-title":"Eur J Cancer"},{"issue":"Suppl 7","key":"BF6604371_CR15","first-page":"53","volume":"38","author":"A Mita","year":"2002","unstructured":"Mita A, Farouzesh B, Hidalgo M, Takimoto C, Norris J, Nadler P, Wood D, Zitelli A, Slack J, Rowinsky E (2002) Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (HER1\/EGFR-TK) inhibitor erlotinib (OSI-774; Tarceva) in combination with docetaxel. Eur J Cancer 38 (Suppl 7): 53 (abstract 168)","journal-title":"Eur J Cancer"},{"issue":"16S Part I","key":"BF6604371_CR16","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.1200\/jco.2005.23.16_suppl.1","volume":"23","author":"M Moore","year":"2005","unstructured":"Moore M, Goldstein D, Hamm J, Kotecha J, Gallinger S, Au HJ, Nomikos D, Ding K, Ptaszynski M, Parulekar W (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol 23 (16S Part I): 1S (abstract 1)","journal-title":"J Clin Oncol"},{"key":"BF6604371_CR17","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","volume":"18","author":"JP Neijt","year":"2000","unstructured":"Neijt JP, Engelholm SA, Tuxen MK, S\u00f8rensen PG, Hansen M, Sessa C, de Swart CAM, Hirsch FR, Lund B, van Houwelingen HC (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084\u20133092","journal-title":"J Clin Oncol"},{"key":"BF6604371_CR18","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","volume":"37","author":"R Nicholson","year":"2001","unstructured":"Nicholson R, Gee J, Harper M (2001) EGFR and cancer prognosis. Eur J Cancer 37: S9\u2013S15","journal-title":"Eur J Cancer"},{"key":"BF6604371_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00280-005-0079-3","volume":"57","author":"KR Ouchi","year":"2006","unstructured":"Ouchi KR, Yanagisawa M, Sekiguchi F, Tanaka Y (2006) Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Parmacol 57: 693\u2013702","journal-title":"Cancer Chemother Parmacol"},{"key":"BF6604371_CR20","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194\u20133200","journal-title":"J Clin Oncol"},{"issue":"16","key":"BF6604371_CR21","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","volume":"22","author":"R Perez-Soler","year":"2004","unstructured":"Perez-Soler R, Chachoua A, Hammond LA, Rowkinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (16): 3238\u20133247","journal-title":"J Clin Oncol"},{"key":"BF6604371_CR22","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","volume":"11","author":"RJ Schilder","year":"2005","unstructured":"Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK (2005) Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11: 5539\u20135548","journal-title":"Clin Cancer Res"},{"key":"BF6604371_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123\u2013132","journal-title":"N Engl J Med"},{"key":"BF6604371_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","volume":"22","author":"D Souli\u00e8res","year":"2004","unstructured":"Souli\u00e8res D, Senzer NN, Vokes EE, Hidalgo M, Agarwala S, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77\u201385","journal-title":"J Clin Oncol"},{"key":"BF6604371_CR25","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/sj.bjc.6603055","volume":"94","author":"CS Townsley","year":"2006","unstructured":"Townsley CS, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM (2006) Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 94: 1136\u20131143","journal-title":"Br J Cancer"},{"issue":"16 Part 2","key":"BF6604371_CR26","first-page":"6096S","volume":"9","author":"J Trigo","year":"2003","unstructured":"Trigo J, Baselga J, De Rosa F, Brennscheidt U, Rakhit A, Fettner S, Jones R, Wright T, Tweleves C (2003) A phase Ib study of Tarceva\u2122 plus capecitabine and docetaxel in metastatic breast cancer. Clin Cancer Res 9 (16 Part 2): 6096S (abstract A74)","journal-title":"Clin Cancer Res"},{"key":"BF6604371_CR27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/sj.bjc.6603665","volume":"96","author":"H Uramoto","year":"2007","unstructured":"Uramoto H, Mitsudomi T (2007) Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96: 857\u2013863","journal-title":"Br J Cancer"},{"issue":"16 Part 2","key":"BF6604371_CR28","first-page":"6095S","volume":"9","author":"E Van Cutsem","year":"2003","unstructured":"Van Cutsem E, Beale P, Delord J-P, Verslype C, Clarke S, Couteau C, Rakhit A, Fettner S, Brennscheidt U, Feyereislova A (2003) Tarceva\u2122 (erlotinib) in combination with Xeloda\u00ae (capecitabine) and oxaliplatin in patients with metastatic colorectal cancer: a phase I dose-escalation trial. Clin Cancer Res 9 (16 Part 2): 6095S (abstract A109)","journal-title":"Clin Cancer Res"},{"key":"BF6604371_CR29","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kay SB (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Instit 96: 1682\u20131691","journal-title":"J Natl Cancer Instit"},{"key":"BF6604371_CR30","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","volume":"18","author":"CF Vershraegen","year":"2000","unstructured":"Vershraegen CF, Sittisomwong T, Kudelka AP, de Paula Guedes E, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN, Kavanagh JJ (2000) Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18: 2733\u20132739","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604371","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:33:02Z","timestamp":1684413182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,27]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["BF6604371"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604371","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,27]]}}}